

Attorney's Docket: 021123-0277862
Client Reference: 990217BT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION of:
MÖCKEL ET AL.

Application No.: 09/813,919

Group Art Unit: 1633

Filed: March 22, 2001

Examiner: J. SWITZER

For: NUCLEOTIDE SEQUENCES ENCODING THE DAPC GENE AND PROCESS
FOR THE PRODUCTION OF L-LYSINE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450



AMENDMENT/RESPONSE TRANSMITTAL

Transmitted herewith is an amendment/response for this application.

FEES

The fee for claims and extension of time (37 C.F.R. 1.16 and 1.17) has been
calculated as shown below:

CLAIMS		HIGHEST NO.		PRESENT		RATE		ADDIT.	
REMAINING	AFTER	PREVIOUSLY	PAID FOR	EXTRA				FEE	
AMENDMENT									
TOTAL	7	—	28	=	0	X	\$ 18.00	=	\$ 0.00
INDEP.	5	—	8	=	0	X	\$ 84.00	=	\$ 0.00
FIRST PRESENTATION OF MULTIPLE DEP.						+			
CLAIM						\$	280.00	=	\$ 0.00
TOTAL ADDITIONAL CLAIM FEE								\$	0.00
GRAND TOTAL								\$	0.00



FEE PAYMENT


Authorization is hereby made to charge the amount of \$0.00 to Deposit Account No. 033975. Charge any additional fees required by this paper or credit any overpayment in the manner authorized above. A duplicate of this paper is attached.

Date: July 22, 2003

PILLSBURY WINTHROP LLP
P.O. Box 10500
McLean, VA 22102
(703) 905-2144



THOMAS A. CAWLEY
Reg. No. 40944



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION of: MÖCKEL
et al.

Application No.: 09/813,919

Group Art Unit: 1633

Filed: March 22, 2001

Examiner: J. SWITZER

Title: NUCLEOTIDE SEQUENCES ENCODING THE DAPC GENE AND PROCESS FOR
THE PRODUCTION OF L-LYSINE

RECEIVED
JUL 25 2003
TECH CENTER 1600/2900

July 22, 2003

AMENDMENT AFTER FINAL PURSUANT TO 37 C.F.R. § 1.116

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This is in response to the final official action dated April 22, 2003, wherein the claims were rejected under 35 U.S.C. §112 first paragraph and 35 U.S.C. §103(a). The applicants respectfully traverse in view of the following amendment and remarks.